RG
SLN

Redmile Group’s Silence Therapeutics SLN Stock Holding History

Redmile Group’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.8M Hold
2,164,777
– – 1.6% 15
2026
Q1 		$11.4M Hold
2,164,777
– – 0.76% 21
2025
Q4 		$13.2M Hold
2,164,777
– – 0.97% 17
2025
Q3 		$11.2M Hold
2,164,777
– – 1.09% 22
2025
Q2 		$12.6M Sell
2,164,777
-50,170
-2% -$215K 1.34% 20
2025
Q1 		$6.25M Sell
2,214,947
-184,370
-8% -$900K 0.59% 32
2024
Q4 		$16.5M Buy
2,399,317
+500,000
+26% +$6.45M 1.15% 25
2024
Q3 		$34.5M Sell
1,899,317
-114,979
-6% -$2.14M 2.03% 24
2024
Q2 		$38.3M Sell
2,014,296
-13,373
-0.7% -$284K 2.31% 16
2024
Q1 		$43.8M Buy
+2,027,669
New +$44.1M 1.61% 23

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return

Redmile Group's SLN Position: Q2 2026 in Review

Redmile Group held its Silence Therapeutics (SLN) position steady in Q2 2026 at 2,164,777 shares worth $23.8M. The position accounts for 1.6% of the portfolio, ranked #15.

Redmile Group first reported a position in SLN in Q1 2024 and has held it in 10 quarters since. The position peaked at $43.8M in Q1 2024. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • Redmile Group held 2,164,777 shares of Silence Therapeutics worth $23.8M as of Q2 2026.
  • Redmile Group left its Silence Therapeutics share count unchanged in Q2 2026.
  • Silence Therapeutics made up 1.6% of Redmile Group's portfolio in Q2 2026, its #15 holding.
  • Redmile Group first reported a position in Silence Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • Redmile Group's Silence Therapeutics position peaked at $43.8M in Q1 2024.
  • 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on Redmile Group's 13F filing for Q2 2026, filed 14 Aug 2026.